Downregulation of BAG‑1 in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway

Lu,Su; Du,Yiyi; Cui,Fang; Feng,Xinyi; Ma,Yuanyuan; Liu,Hong

doi:10.3892/or.2019.6978

Downregulation of BAG‑1 in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway

Authors:
- Su Lu
- Yiyi Du
- Fang Cui
- Xinyi Feng
- Yuanyuan Ma
- Hong Liu
View Affiliations

Affiliations: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin 300060, P.R. China, Department of Oncology, Yixing Hospital Affiliated to Jiangsu University, Yixing, Jiangsu 214200, P.R. China
Published online on: January 22, 2019 https://doi.org/10.3892/or.2019.6978
Pages: 1901-1910

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tamoxifen, a selective estrogen receptor (ER) modulator, is the most widely used endocrine therapy for patients with ER‑positive breast cancer. However, ~30% of tamoxifen‑treated breast cancers do not initially respond to tamoxifen, and neither do they eventually develop tamoxifen resistance. Bcl‑2‑associated athanogene 1 (BAG‑1) is a multifunctional protein that interacts with a wide range of molecules to protect cells from apoptosis otherwise induced by cytotoxic drugs, growth factor withdrawal, radiation and stress. The aim of the present study was to investigate the function of BAG‑1 in tamoxifen resistance. Immunohistochemistry techniques were used to determine BAG‑1 expression in 119 stage I‑III primary breast cancer tissues and it was identified that BAG‑1 was significantly overexpressed in ER‑positive breast cancer (P=0.001). Knockdown of BAG‑1 by short interfering RNA was revealed to downregulate ER, and upregulate phospho (p)‑protein kinase B (Akt) and p‑mammalian target of rapamycin (mTOR) levels. Furthermore, significantly decreased tamoxifen‑induced apoptosis (41.70±1.93 vs. 55.03±2.39%; P=0.012) was observed in T47D cells following the silencing of BAG‑1. In contrast, overexpression of BAG‑1 long enhanced apoptosis (65.10±2.35 vs. 55.03±2.39%; P=0.039) in T47D cells treated with tamoxifen. Combination treatment of tamoxifen and an mTOR inhibitor restored the inhibitory effects of tamoxifen in T47D cells exhibiting low BAG‑1 expression levels (66.87±2.27 vs. 57.07±2.46%; P=0.037). In conclusion, there results of the present study indicated that suppression of BAG‑1 expression may activate the phosphoinositide 3‑kinase/Akt/mTOR pathway and protect ER‑positive breast cancer cells from tamoxifen‑induced inhibition of proliferation. ER‑positive breast cancer cells exhibiting low BAG‑1 expression appeared to be more sensitive to treatment with the mTOR inhibitor rapamycin. Furthermore, the results indicated that combination treatment targeting ER with tamoxifen and targeting mTOR with rapamycin may significantly potentiate the inhibitory effect in BAG‑1‑silenced cells.

View Figures

View References

1	Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC and Henderson BE: Breast cancer risk factors defined by estrogen and progesterone receptor status: The multiethnic cohort study. Am J Epidemiol. 169:1251–1259. 2009. View Article : Google Scholar : PubMed/NCBI
2	Li CI, Daling JR and Malone KE: Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol. 21:28–34. 2003. View Article : Google Scholar : PubMed/NCBI
3	Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet. 339:71–85. 1992.PubMed/NCBI
4	Yue W, Fan P, Wang J, Li Y and Santen RJ: Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol. 106:102–110. 2007. View Article : Google Scholar : PubMed/NCBI
5	Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA and Reed JC: Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activity. Cell. 80:279–284. 1995. View Article : Google Scholar : PubMed/NCBI
6	Wang HG, Takayama S, Rapp UR and Reed JC: Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc Natl Acad Sci USA. 93:7063–7068. 1996. View Article : Google Scholar : PubMed/NCBI
7	Takayama S, Bimston DN, Matsuzawa S, Freeman BC, Aime-Sempe C, Xie Z, Morimoto RI and Reed JC: BAG-1 modulates the chaperone activity of Hsp70/Hsc70. EMBO J. 16:4887–4896. 1997. View Article : Google Scholar : PubMed/NCBI
8	Devireddy LR, Kumar KU, Pater MM and Pater A: BAG-1, a novel Bcl-2-interacting protein, activates expression of human JC virus. J Gen Virol. 81:351–357. 2000. View Article : Google Scholar : PubMed/NCBI
9	Zhou R, Gray NA, Yuan P, Li X, Chen J, Chen G, Damschroder-Williams P, Du J, Zhang L and Manji HK: The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci. 25:4493–4502. 2005. View Article : Google Scholar : PubMed/NCBI
10	Hinitt CA, Wood J, Lee SS, Williams AC, Howarth JL, Glover CP, Uney JB and Hague A: BAG-1 enhances cell-cell adhesion, reduces proliferation and induces chaperone-independent suppression of hepatocyte growth factor-induced epidermal keratinocyte migration. Exp Cell Res. 316:2042–2060. 2010. View Article : Google Scholar : PubMed/NCBI
11	Clemo NK, Collard TJ, Southern SL, Edwards KD, Moorghen M, Packham G, Hague A, Paraskeva C and Williams AC: BAG-1 is up-regulated in colorectal tumour progression and promotes colorectal tumour cell survival through increased NF-kappaB activity. Carcinogenesis. 29:849–857. 2008. View Article : Google Scholar : PubMed/NCBI
12	Wang YD, Ha MW, Cheng J, Zhang WL, Cong X, Tong CY and Sun J: The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC. Oncol Rep. 27:979–986. 2012. View Article : Google Scholar : PubMed/NCBI
13	Ni W, Chen B, Zhou G, Lu C, Xiao M, Guan C, Zhang Y, He S, Shen A and Ni R: Overexpressed nuclear BAG-1 in human hepatocellular carcinoma is associated with poor prognosis and resistance to doxorubicin. J Cell Biochem. 114:2120–2130. 2013. View Article : Google Scholar : PubMed/NCBI
14	Ozfiliz P, Kizilboga T, Demir S, Alkurt G, Palavan-Unsal N, Arisan ED and Dinler-Doganay G: Bag-1 promotes cell survival through c-Myc-mediated ODC upregulation that is not preferred under apoptotic stimuli in MCF-7 cells. Cell Biochem Funct. 33:293–307. 2015. View Article : Google Scholar : PubMed/NCBI
15	Papadakis E, Robson N, Yeomans A, Bailey S, Laversin S, Beers S, Sayan AE, Ashton-Key M, Schwaiger S, Stuppner H, et al: A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells. Oncotarget. 7:18851–18864. 2016. View Article : Google Scholar : PubMed/NCBI
16	Packham G, Brimmell M and Cleveland JL: Mammalian cells express two differently localized Bag-1 isoforms generated by alternative translation initiation. Biochem J. 328:807–813. 1997. View Article : Google Scholar : PubMed/NCBI
17	Takayama S, Krajewski S, Krajewska M, Kitada S, Zapata JM, Kochel K, Knee D, Scudiero D, Tudor G, Miller GJ, et al: Expression and location of Hsp70/Hsc-binding anti-apoptotic protein BAG-1 and its variants in normal tissues and tumor cell lines. Cancer Res. 58:3116–3131. 1998.PubMed/NCBI
18	Millar EK, Anderson LR, McNeil CM, O'Toole SA, Pinese M, Crea P, Morey AL, Biankin AV, Henshall SM, Musgrove EA, et al: BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. Br J Cancer. 100:123–133. 2009. View Article : Google Scholar : PubMed/NCBI
19	Cutress RI, Townsend PA, Sharp A, Maison A, Wood L, Lee R, Brimmell M, Mullee MA, Johnson PW, Royle GT, et al: The nuclear BAG-1 isoform, BAG-1L, enhances oestrogen-dependent transcription. Oncogene. 22:4973–4982. 2003. View Article : Google Scholar : PubMed/NCBI
20	Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 351:2817–2826. 2004. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Chen JM, Dando PM, Stevens RA, Fortunato M and Barrett AJ: Cloning and expression of mouse legumain, a lysosomal endopeptidase. Biochem J. 335:111–117. 1998. View Article : Google Scholar : PubMed/NCBI
23	Ciruelos Gil EM: Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev. 40:862–871. 2014. View Article : Google Scholar : PubMed/NCBI
24	Ghayad SE, Bieche I, Vendrell JA, Keime C, Lidereau R, Dumontet C and Cohen PA: mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 99:1992–2003. 2008.PubMed/NCBI
25	Chang SB, Miron P, Miron A and Iglehart JD: Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. J Surg Res. 138:37–44. 2007. View Article : Google Scholar : PubMed/NCBI
26	Brimmell M, Burns JS, Munson P, McDonald L, O'Hare MJ, Lakhani SR and Packham G: High level expression of differentially localized BAG-1 isoforms in some oestrogen receptor-positive human breast cancers. Br J Cancer. 81:1042–1051. 1999. View Article : Google Scholar : PubMed/NCBI
27	Turner BC, Krajewski S, Krajewska M, Takayama S, Gumbs AA, Carter D, Rebbeck TR, Haffty BG and Reed JC: BAG-1: A novel biomarker predicting long-term survival in early-stage breast cancer. J Clin Oncol. 19:992–1000. 2001. View Article : Google Scholar : PubMed/NCBI
28	Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR, Powe DG, Robertson JF, Aparicio S, Ellis IO, Brenton JD, et al: A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene. 26:1507–1516. 2007. View Article : Google Scholar : PubMed/NCBI
29	Moriyama T, Littell RD, Debernardo R, Oliva E, Lynch MP, Rueda BR and Duska LR: BAG-1 expression in normal and neoplastic endometrium. Gynecol Oncol. 94:289–295. 2004. View Article : Google Scholar : PubMed/NCBI
30	Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A and DeGraffenried LA: Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol. 18:1323–1328. 2007. View Article : Google Scholar : PubMed/NCBI
31	McCubrey JA, Davis NM, Abrams SL, Montalto G, Cervello M, Libra M, Nicoletti F, D'Assoro AB, Cocco L, Martelli AM and Steelman LS: Targeting breast cancer initiating cells: Advances in breast cancer research and therapy. Adv Biol Regul. 56:81–107. 2014. View Article : Google Scholar : PubMed/NCBI
32	Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, et al: PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther. 10:1093–1101. 2011. View Article : Google Scholar : PubMed/NCBI
33	Pérez-Tenorio G and Stål O; Southeast Sweden Breast Cancer Group, : Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer. 86:540–545. 2002. View Article : Google Scholar : PubMed/NCBI
34	Tokunaga E, Kimura Y, Oki E, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Baba H and Maehara Y: Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer. 118:284–289. 2006. View Article : Google Scholar : PubMed/NCBI
35	Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S and Nakshatri H: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance. J Biol Chem. 276:9817–9824. 2001. View Article : Google Scholar : PubMed/NCBI
36	deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA and Hidalgo M: Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res. 10:8059–8067. 2004. View Article : Google Scholar : PubMed/NCBI
37	Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 366:520–529. 2012. View Article : Google Scholar : PubMed/NCBI
38	Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, et al: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol. 30:2718–2724. 2012. View Article : Google Scholar : PubMed/NCBI